Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Other Non Operating Income: 2019-2025

Historic Other Non Operating Income for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$2.8 million.

  • Beam Therapeutics' Other Non Operating Income fell 1278.50% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522,000, marking a year-over-year increase of 4.40%. This contributed to the annual value of $2.3 million for FY2024, which is 69.71% down from last year.
  • Latest data reveals that Beam Therapeutics reported Other Non Operating Income of -$2.8 million as of Q3 2025, which was down 340.37% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Other Non Operating Income ranged from a high of $35.8 million in Q3 2021 and a low of -$42.3 million during Q2 2021.
  • Its 3-year average for Other Non Operating Income is $947,455, with a median of -$128,000 in 2024.
  • In the last 5 years, Beam Therapeutics' Other Non Operating Income skyrocketed by 1,225.93% in 2021 and then slumped by 1,278.50% in 2025.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Other Non Operating Income stood at $7.4 million in 2021, then plummeted by 59.46% to $3.0 million in 2022, then crashed by 163.33% to -$1.9 million in 2023, then surged by 93.26% to -$128,000 in 2024, then tumbled by 1,278.50% to -$2.8 million in 2025.
  • Its Other Non Operating Income was -$2.8 million in Q3 2025, compared to $1.1 million in Q2 2025 and $2.3 million in Q1 2025.